Morgan Stanley raised the firm’s price target on Denali Therapeutics (DNLI) to $42 from $40 and keeps an Overweight rating on the shares after the company received FDA accelerated approval for its treatment for Hunter syndrome ahead of its April 5 PDUFA deadline. The firm sees the approval as “the start of a paradigm shift in treatment of MPS II/III and other lysosomal storage disorders,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target raised to $31 from $29 at BofA
- Denali Therapeutics price target raised to $41 from $34 at Stifel
- Denali Therapeutics price target raised to $32 from $29 at Baird
- Denali Therapeutics: AVLAYAH’s Superior Efficacy, BBB Shuttle Platform, and Robust Pipeline Support Buy Rating and Higher Target
- Denali Therapeutics: Avlayah Launch and Platform De-Risking Support Commercial Upside and Higher Valuation